PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.06%
EBIT growth below 50% of TRVN's 22.49%. Michael Burry would suspect deeper competitive or cost structure issues.
7.06%
Operating income growth under 50% of TRVN's 22.49%. Michael Burry would be concerned about deeper cost or sales issues.
10.36%
Net income growth under 50% of TRVN's 21.70%. Michael Burry would suspect the firm is falling well behind a key competitor.
28.30%
EPS growth 1.25-1.5x TRVN's 24.00%. Bruce Berkowitz would check if strategic initiatives like cost cutting or better capital management explain the difference.
28.30%
Diluted EPS growth 1.25-1.5x TRVN's 24.00%. Bruce Berkowitz would verify if strategic moves (e.g., targeted acquisitions, cost cuts) explain the edge.
24.68%
Share count expansion well above TRVN's 2.97%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
24.68%
Diluted share count expanding well above TRVN's 2.97%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
17.79%
OCF growth under 50% of TRVN's 36.05%. Michael Burry might suspect questionable revenue recognition or rising costs.
17.79%
FCF growth 50-75% of TRVN's 35.28%. Martin Whitman would see if structural disadvantages exist in generating free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19298.96%
Negative 10Y OCF/share CAGR while TRVN stands at 23.38%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-3628.66%
Negative 5Y OCF/share CAGR while TRVN is at 23.38%. Joel Greenblatt would question the firm’s operational model or cost structure.
45.61%
3Y OCF/share CAGR at 75-90% of TRVN's 53.14%. Bill Ackman would press for improvements in margin or overhead to catch up.
-15204.15%
Negative 10Y net income/share CAGR while TRVN is at 10.15%. Joel Greenblatt sees a major red flag in long-term profit erosion.
97.68%
5Y net income/share CAGR above 1.5x TRVN's 10.15%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
59.13%
3Y net income/share CAGR similar to TRVN's 54.83%. Walter Schloss would attribute it to shared growth factors or demand patterns.
9892.41%
Equity/share CAGR of 9892.41% while TRVN is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
293.35%
Equity/share CAGR of 293.35% while TRVN is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
201.29%
Positive short-term equity growth while TRVN is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
67.39%
Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
64.49%
Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
13.21%
We increase R&D while TRVN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-38.56%
We cut SG&A while TRVN invests at 19.32%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.